MPL and autoimmune thrombocytopenic purpura: EPAG is an orally thrombopoietin receptor agonist already approved for ITP treatment in pediatric patients (Burness et al., 2016; Wong et al., 2017; Kim et al., 2018; Fattizzo et al., 2019).